Flurbiprofen

References

• Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases
  • R. N. Brogden, R. C. Heel, T. M. Speight, G. S. Avery, Drugs 1979, 18, 417.
• Flurbiprofen (a review)
  • A. A.-M. Abdel-Aziz, A. A. Al-Badr, G. A. Hafez, Profiles Drug Subst, Excipients, Related Method. 2012, 37, 113.
• New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers (a review)
  • G. Geisslinger, H.-G. Schaible, J. Clin. Pharmacol. 1996, 36, 513.
• NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
  • J. L. Eriksen, S. A. Sagi, T. E. Smith, S. Weggen, P. Das, D. C. McLendon, V. V. Ozols, K. W. Jessing, K. H. Zavitz, E. H. Koo, T. E. Golde, J. Clin. Invest. 2003, 112, 440.
• Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease (a review)
  • L. Gasparini, E. Ongini, D. Wilcock, D. Morgan, Brain Res. Rev. 2005, 48, 400.
• Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease (a review)

  
  
  Anwendung
  Binding of Flurbiprofen to Human Serum Albumin
  Flurbiprofen is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site II on HSA. Those were confirmed using our ibuprofen with Surface Plasmon Resonance (SPR) and a method using fluorescent probes. 【SPR】Dose responses of flurbiprofen to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.

  

  ＜Assay condition＞ Sensor Chip: Series S Sensor Chip CM5, Immobilization: HAS (Amine Coupling method), Buffer : 5%DMSO in PBS. ＜Result＞ “Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of flurbiprofen to HSA was confirmed. 【Method using fluorescent probes】The drug biding site of flurbiprofen was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.

  

  ＜Assay condition＞ Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Flurbiprofen: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140). ＜Result＞ As shown in upper diagram, inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II by flurbiprofen was confirmed. And also, little or extremely weak inhibition against binding of dansylamide which is fluorescent probe for site I was confirmed. In these ways, our flurbiprofen can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.

  References

  • Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
    • J. C. Er, M. Vendrell, M. K. Tang, D. Zhai, Y. T. Chang, ACS Comb. Sci. 2013, 15, 452.
  • High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
    • R. L. Rich, Y. S. Day, T. A. Morton , D. G. Myszka, Anal Biochem. 2001, 296, 197.
  • Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
    • Å. Frostell-Karlsson, A. Remaeus, H. Roos, K. Andersson, P. Borg, M. Hämäläinen, R. Karlsson, J. Med. Chem. 2000, 43, 1986.
  • Characterizing a drug's primary binding site on albumin
    • Y. S. Day, D. G. Myszka, J. Pharm. Sci. 2003, 92, 333.
  • Structural basis of the drug-binding specificity of human serum albumin
    • J. Ghuman, P. A. Zunszain,I. Petitpas, A. A. Bhattacharya, M. Otagiri, S. Curry, J. Mol. Biol. 2005, 353, 38.
  
  
  PubMed Literatur